Market research
VCYT Veracyte Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- 30.27
- Analyst target
- 57.8182
- Dividend yield
- Not available
- Beta
- 1.94
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US92337F1075
- Market cap
- 3B
- P/E ratio
- 30.27
- Analyst target
- 57.8182
- Dividend yield
- Not available
- Beta
- 1.94
About
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VCYT discussion.
5 years, 4 months ago
Veracyte, Inc is currently in a long term downtrend where the price is trading 17.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 25.7.
Veracyte, Inc's total revenue rose by 16.2% to $35M since the same quarter in the previous year.
Its net income has increased by 100.4% to $27K since the same quarter in the previous year.
Finally, its free cash flow grew by 99.0% to $1M since the same quarter in the previous year.
Based on the above factors, Veracyte, Inc gets an overall score of 4/5.